论文部分内容阅读
目的 :探讨前列地尔、贝那普利联合用于糖尿病肾病蛋白尿的可行性。方法 :选取于2012年的12月份到2013年12月份期间我院接收治疗的72例糖尿病肾病蛋白尿患者,随机分配为两组,实验组(36例)联合应用前列地尔与贝那普利治疗,对照组(35例)采用贝那普利治疗。结果 :经过1个月治疗后,实验组24h尿蛋白定量、24小时尿微蛋白排泄的量得到了显著的降低,明显比对照组的地,P<0.05,完成30天的治疗后,实验组总有效率94.44%,对照组为69.44%,P<0.05。结论 :前列地尔、贝那普利联合用于糖尿病肾病蛋白尿治疗,能显著改善糖尿病肾病患者的蛋白尿水平。
Objective: To investigate the feasibility of combination of alprostadil and benazepril for diabetic nephropathy. Methods: A total of 72 diabetic nephropathy patients with proteinuria receiving treatment in our hospital from December 2012 to December 2013 were randomly assigned to two groups. The experimental group (36 patients) was treated with combination of alprostadil and benazepril Treatment, control group (35 cases) with benazepril treatment. Results: After 1 month of treatment, the urinary protein excretion of 24 hours in the experimental group was significantly lower than that of the control group (P <0.05). After 30 days of treatment, the experimental group The total effective rate was 94.44%, while the control group was 69.44%, P <0.05. Conclusion: Alprostadil and benazepril combined with proteinuria for diabetic nephropathy can significantly improve proteinuria in patients with diabetic nephropathy.